- Home
- EAF vs CLLS Comparison
EAF vs CLLS Comparison
Compare EAF & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | CLLS |
|---|---|---|
| Founded | 1886 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.4M | 384.3M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EAF | CLLS |
|---|---|---|
| Price | $7.73 | $4.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $11.75 | $8.50 |
| AVG Volume (30 Days) | ★ 215.8K | 37.7K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,134,000.00 | N/A |
| Revenue This Year | $4.25 | N/A |
| Revenue Next Year | $12.49 | $0.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $1.33 |
| 52 Week High | $20.32 | $5.48 |
Technical Indicators
Market Signals| Indicator | EAF | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 59.18 | 69.97 |
| Support Level | $7.65 | $3.39 |
| Resistance Level | $7.73 | $4.46 |
| Average True Range (ATR) | 0.64 | 0.20 |
| MACD | 0.28 | 0.10 |
| Stochastic Oscillator | 87.21 | 85.90 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.